Bibliography
- CALDERWOOD DJ, JOHNSTON DN, MUNSCHAUER R, RAFFERTY P: Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potential inhibitors of Lck. Bioorg. Med. Chem. Lett. (2002) 12:1683–1686.
- ARNOLD LD, CALDERWOOD DJ, DIXON RW et al: Pyrrolo [2,3-d] pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck I. Bioorg. Med. Chem. Lett. (2000) 10:2167–2170.
- BURCHAT AF, CALDERWOOD DJ, FRIEDMAN MM et al: Pyrazolo [3,4-d] pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. Bioorg. Med. Chem. Lett. 12:1687-1690.
- BURCHAT AF, CALDERWOOD DJ, HIRST GC et al.: Pyrrolo [2,3-d] pyrimidines containing an extended 5-substituent as potent an selective inhibitors of Lck II. Bioorg. Med. Chem. Lett. (2000) 10:2171–2174.
- NISHIMURA R, HATA K, IKEDA F et al.: The role of Smads in BMP signaling. Front. Biosci. (2003) 8:s275–s284.
- •A review on the Smads and the BMP pathway.
- MIYAZAWA K, SHINOZAKI M, HARA T, FURUYA T, MIYAZONO K: Two major Smad pathways in TGF-I3 superfamily signalling. Genes to Cells (2002) 7:1191–1204.
- •A review of the Smad pathways in TGE-13 signalling.
- GAULDIE J, GALT T, BONNIAUD P et al.: Transfer of the active form of transforming growth factor-I3 1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia. Am. Path (2003) 163:2574–2584.
- ••Development of a key animal model forthe study of lung remodelling.
- KRAVCHENKO VV, MATHISON JC, SCHWAMBORN K, MERCURIO F, ULEVITCH RJ: IKK/IKKE plays a key role in integrating signals induced by pro-inflammatory stimuli. J. Biol. Chem. (2003) 278:26612–26619.
- YU PH, WRIGHT S, FAN EH, LUN ZR,GUBISNE-HARBERLE D: Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim. Biophys. Acta (2003) 1647:193–199.
- •A review on SSAOs and their role in physiology.
- TREMBLAY GM, JANELLE MF, BOURBONNAIS Y: Anti-inflammatory activity of neutrophil elastase inhibitors. Curr. Opin. Invest. Drugs (2003) 4:556–565.
- GRECO MN, HAWKINS MJ, POWELL ET et al.: Nonpeptide inhibitors of cathepsin G: optimisation of a novel P-ketophosphonic acid lead by structure-based drug design. I Am. Chem. Soc. (2002) 124:3810–3811.
- ADAMS J: Potential for proteasome inhibition in the treatment of cancer. Drug Discov. Today(2003) 8:307–315.
- KANE RC, BROSS PF, FARRELL AT, PAZDUR R: Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist (2003) 8:508–513.
- ••Progression of PS-341 for the treatment ofmultiple myeloma.
- ELLIOTT PJ, ZOLLNER TM, BOEHNCKE WH: Proteasome inhibition: a new anti-inflammatory strategy.' Ma Med. (2003) 81:235–245.
- ••A review of mechanisms that target theproteome.
- BILLICH A, ASCHAUER H, ASZODI A, STUETZ A: Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int. Pharmaceutics (2004) 269:29–35.
- ••Differentiation between corticosteroidsand immunophilins.
- MEINGASSNER JG, FAHRNGRUBER H, BAVANDI A: Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine. J. Invest. Dermatol (2003) 121:77–80.
- HIESTAND PC, FEIFEL R, STUETZ A: Pimecrolimus is highly effective in two rat models of rheumatoid arthritis. Inflamm. Res. (2003) (Suppl. 2):5157.
- •Emerging data on the use of pirnecrolimus in RA.
- SAUDER DN: Imiquimod: modes of action. Br. J. Dermatol (2003) 149\(Suppl. 66):5–8.
- TRAN H, CHEN K, SHUMACK S et al: Summary of actinic keratosis studies with imiquimod 5% cream. Br. I Dermatol (2003) 149\(Suppl. 66):37–39.
- IOANNOU XP, GOMIS SM, KARVONEN B et al: CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine (2002) 21:127–137.
- SANDS BE, ANDERSON FH, BERNSTEIN CN et al: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl. I Med. (2004) 350: 876–885.
- ••Further evidence that infliximab iseffective in maintenance therapy.
- CARPENTER PA, APPELBAUM FR, COREY L et al.: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood (2002) 99:2712–2719.
- WASSERMAN MA, SUNDELL CL, KUNSCH C et al.: Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am. I Cardiol (2003) 91:34A–40A.
- KUNSCH C, LUCHOOMUN J, GREY JY et al.: Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: A novel antioxidant and anti-inflammatory agent. Pharmacol Exp. Ther. (2004) 308:820–829.
- ••A new class of compounds: vascularprotectants.
- SUNDELL CL, SOMERS PK, MENG CQ et al: AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. Pharm. Exp. Thec (2003) 305:1116–1123.
- STEED PM, TANSEY MG, ZALEVSKY J et al.: Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 301:1895–1898.
- ••Rationally designed immuno-screened DNproteins as competitors for trimer formation.
- BRADDOCK M, QUINN A: Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev Drug Disc. (2004) 3:330–340.
- ••A review of IL-1 in inflammatory diseaseand current routes to neutralisation/ inhibition.
- LALIBERTE RE, PERREGAUX DG, HOTH LR et al.: Glutathione ..Ctransferase omega 1–1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-113 post-translational processing. J. Biol. Chem. (2003) 278:16567–16578.
- ••Identification of the molecular target ofthe CRID compounds.
- GORDON SM, BRAHIM JS, PICCO CC, ROWAN J, DIONNE RA: Etanercept suppresses acute pain and PGE2 at the site of injury. Clin. Pharm. (2002) 71:38.
- BARNES PJ, ITO K, ADCOCK IM: Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet (2004) 363:731-733. A thought-provoking review on the role of histone acetylation in response to corticosteroids.
- REINHARDT RL, JENKINS MK: Whole-body analysis of T cell responses. Carr Opin Immunol. (2003) 15:366–371.
- CAHALAN MD, PARKER I, WET SH, MILLER MJ: Real-time imaging of lymphocytes in vivo. Carr. Opin. ImmunoL (2003) 15:372–377.
- GARSIDE P, INGULLI E, MERICA RR et al.: Visualization of specific B and T lymphocyte interactions in the lymph node. Science (1998) 281:96–99.
- ADAMS CL, AITKEN R, MILNER-WHITE J, GARSIDE P, STOTT DI: Complete analysis of the B-cell response to a protein antigen, from in vivo germinal centre formation to 3-D modelling of affinity maturation.Immunology (2003) 108:274–287.
- ••Visualising the immune response in vivo. Websites
Websites
- http://www.Coleypharma.com Coley Pharaceuticals website.
- http://www.direvo.com Direvo Biotech website. Affiliation